Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [5][21] - Fourth quarter revenue was $11.4 million, the highest revenue quarter of the year, up 13% from the third quarter but down slightly year-over-year [15][19] - Gross margin for the fourth quarter was 68.6%, down from 71.4% a year ago, but up from 63.8% in the third quarter [19][21] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [20][21] - Net loss for the fourth quarter was $3.8 million, or $0.09 per share, compared to a net loss of $300,000 or $0.01 per share for the same quarter last year [20][21] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved quarterly revenue exceeding $1 million for the first time, up 81% year-over-year [7][18] - International revenue reached a record $2.2 million, up 46% year-over-year, representing 19% of total revenue [18] - The company recorded 241 MyoPros ordered during the fourth quarter, up 5% sequentially from the third quarter [5][19] - Recurring patient sources, including referrals under the MyoConnect program, represented 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [8][18] Market Data and Key Metrics Changes - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a multi-state agreement with Elevance Health covering 45 million lives [10][11] - The patient pipeline stood at 1,528 patients as of December 31, 2025, an increase of 10% year-over-year [18] - The company faced challenges with Medicare Advantage payers, which issued a high number of pre-authorization denials [16][17] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [4] - A strategic pivot towards recurring patient sources is evident, with a focus on the MyoConnect program to engage therapists and physicians [8][12] - The company plans to limit advertising spending while building out the MyoConnect program and adding direct sales resources [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the O&P channel and international markets, despite challenges with Medicare Advantage [10][17] - The company expects revenue in 2026 to be in the range of $43 million to $46 million, with a focus on recurring sources [23][24] - Management anticipates a reduction in cash burn by roughly half in 2026 compared to 2025 [24] Other Important Information - The company launched the MyoPro Center of Excellence program to educate O&P practices on the new MyoPro 2X product [6] - A randomized controlled trial is being conducted to further validate the MyoPro's effectiveness, with results expected by the end of the year [79] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the MyoConnect program? - Management noted that the fourth quarter typically has higher advertising costs due to competition and that a new marketing head and agency have been brought on to address this [34][35] Question: Can you provide KPIs around the O&P channel? - The company has trained and certified a couple of dozen O&P providers, generating over $1 million in revenue in the quarter [38][39] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth is expected in the O&P channel and international markets, while direct billing is anticipated to remain flat [41][42] Question: What is the status of the pipeline ads and dropout rate? - The pipeline ads were lower due to a shutdown in late December, and the dropout rate was noted to be around 20% [46][50] Question: How is the German market performing? - The German market is growing well due to favorable reimbursement policies and a strong recruitment of O&P practices [78] Question: What is the timeline for the MyoPro 3 model? - The MyoPro 3 will be a next-generation platform with significant improvements, but specific timelines were not provided [81]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [9][25] - Fourth quarter revenue was $11.4 million, the highest quarterly revenue of the year, up 13% sequentially but down slightly year-over-year [25][9] - Gross margin for the fourth quarter was 68.6%, down from 71.4% year-over-year but up from 63.8% in the previous quarter [34][25] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [36][37] - Net loss for the fourth quarter was $3.8 million, or $0.09 per share, compared to a net loss of $300,000 or $0.01 per share for the same quarter last year [37][25] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved record quarterly revenue of over $1 million, up 81% year-over-year [32][11] - International revenue reached a record $2.2 million, up 46% year-over-year, primarily driven by growth in Germany [32][15] - The number of MyoPro units ordered in the fourth quarter was 241, up 5% sequentially [9][10] - Recurring patient sources represented 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [13][32] Market Data and Key Metrics Changes - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a multi-state agreement with Elevance Health covering 45 million lives [19][18] - The patient pipeline stood at 1,528 patients, an increase of 10% year-over-year [33][25] - The company faced challenges with Medicare Advantage payers, resulting in a decrease in authorizations and revenue from this segment [28][29] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [7][9] - A focus on managing cost structure and enhancing manufacturing processes to demonstrate operating leverage as the company scales [8][21] - Continued innovation in product development, including the launch of the MyoPro 2X and plans for the MyoPro 3 [46][39] - The strategic pivot towards recurring patient sources is expected to reduce customer acquisition costs and improve operating leverage [23][45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the O&P channel and international markets [90][91] - The company anticipates a challenging environment with Medicare Advantage payers but is working to secure more payer contracts [29][62] - For 2026, the company expects revenue in the range of $43 million to $46 million, with a focus on recurring sources [43][45] - Management aims to reduce cash burn by approximately 50% in 2026 compared to 2025 [45][41] Other Important Information - The company is investing in R&D, including a randomized controlled trial to support the efficacy of MyoPro [23][104] - The MyoConnect program has generated over 100 qualified candidates in its first six months, contributing to the patient pipeline [12][11] - The company plans to activate the Myomo mobile app for patients and clinicians, which is expected to reduce costs [21][23] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the fourth quarter? - Management noted that higher advertising costs in the fourth quarter were due to competition with holiday advertising and election cycles [55] Question: Can you provide details on the O&P channel's performance? - The company reported over $1 million in revenue from the O&P channel, with approximately 36 units ordered in the fourth quarter [60] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth in the O&P channel and international markets is expected to drive overall growth, while direct billing is anticipated to remain flat [61] Question: What is the current status of the pipeline ads and dropout rates? - The pipeline ads were lower due to a shutdown in the last days of 2025, and the dropout rate was affected by challenges in obtaining authorizations from Medicare Advantage [66][70] Question: How does the company plan to use data from the randomized controlled trial? - The data will be used to convince payers of the MyoPro's medical necessity and to support reimbursement efforts [104] Question: What is the expected gross margin for international operations compared to domestic? - International gross margins are expected to be slightly lower than domestic margins, but both will benefit from increased volume [110]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [5][21] - Fourth quarter revenue was $11.4 million, the highest revenue quarter of the year, up 13% from the third quarter but down slightly year-over-year [14][19] - Gross margin for the fourth quarter was 68.6%, down from 71.4% a year ago, but up from 63.8% in the third quarter [19] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [20] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved quarterly revenue exceeding $1 million for the first time, up 81% year-over-year [6][18] - Revenue from the O&P channel was up 81% for the quarter and doubled for the year [6][8] - The MyoConnect program contributed to 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [8] Market Data and Key Metrics Changes - International operations delivered quarterly revenues exceeding $2 million for the first time, growing 46% for the quarter and 48% for the year [8][18] - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a significant agreement with Elevance Health covering 45 million lives [10] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [4] - A focus on managing cost structure and enhancing manufacturing processes to demonstrate operating leverage as the company scales [4] - Continued innovation in product development to maintain market leadership, including the launch of the MyoPro 2X and development of MyoPro 3 [12][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth in recurring patient sources and the MyoConnect program, which is expected to reduce customer acquisition costs [8][28] - The company anticipates a revenue range of $43 million to $46 million for 2026, with a focus on stroke patients and recurring sources [24][25] - Management acknowledged challenges with Medicare Advantage payers but is encouraged by new payer contracts leading to more authorizations [17][41] Other Important Information - The company plans to activate the Myomo mobile app for patients and clinicians, which is expected to reduce costs associated with shipping laptops [12] - Cash burn was reported at $1.5 million in the fourth quarter, with operating cash flow negative at $1.1 million [22] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the MyoConnect program? - Management noted that the fourth quarter typically has higher advertising costs due to competition and has implemented changes to reduce costs moving forward [34][35] Question: Can you provide details on the O&P channel's performance? - The O&P channel had over $1 million in revenue with approximately 36 units ordered in the fourth quarter [39] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth is expected in the O&P channel and international markets, while direct billing is anticipated to remain flat [40][41] Question: What is the current status of the pipeline and dropout rates? - The pipeline added 676 patients, slightly lower than previous quarters, with a dropout rate around 20% due to challenges with Medicare Advantage authorizations [45][56] Question: What is the expected gross margin for the upcoming quarters? - Management expects first quarter gross margin to be lower than the fourth quarter but aims to improve gross margin to the 70% range by the end of 2026 [59][61]

Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results-# Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsShare---Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million42% of fourth quarter revenue from recurring patient sourcesRecord 241 authorizations and orders in the quarterIntroduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenueConference call begins today at 4:30pm Easte ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $10.1 million, a 10% increase year-over-year, driven by a higher number of revenue units despite a lower average selling price (ASP) [16][4] - The company delivered 186 MyoPro revenue units, up 16%, with 57% of those units from authorizations and orders received in Q3 [16] - ASP decreased by 5% year-over-year to approximately $54,300, but normalized for accounting changes, ASP increased by 3% [16][17] - Gross margin for Q3 2025 was 63.8%, down from 75.4% in the prior year, impacted by higher payroll, lease expenses, and material costs [20][21] - Operating loss for Q3 2025 was $3.5 million, compared to a loss of $1 million in the prior year [23] Business Line Data and Key Metrics Changes - International revenue reached a record $1.8 million, up 63%, primarily from Germany, representing 18% of total revenue [18] - Revenue from the O&P channel was a record $900,000, up 154% year-over-year, representing 9% of total revenue [18] - The pipeline stood at 1,669 patients, a 32% increase year-over-year, with 826 patients added in Q3 [19] Market Data and Key Metrics Changes - Medicare Part B patients represented 54% of revenue in Q3, while Medicare Advantage revenue was 18%, down 18% year-over-year due to high pre-authorization denials [17] - The company signed an additional contract with a payer, increasing covered lives to 35 million among private payers [12] Company Strategy and Development Direction - The company aims to diversify revenue streams, focusing less on advertising-driven revenues and more on the MyoPro Connect platform and O&P channel penetration [26] - Key initiatives include improving patient identification, expanding the MyoPro Connect program, and reducing operating costs [5][14] - The company is enhancing manufacturing processes to improve gross margin and operating leverage as revenues grow [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the O&P channel and the MyoPro Connect program, expecting to see more patient pipeline adds through these channels [40] - The company reiterated its full-year 2025 revenue guidance of $40-$42 million, representing over 23% growth from the previous year [14][26] Other Important Information - The company entered into a loan agreement providing a term loan facility of $17.5 million to support growth and operational needs [25] - Cash balance as of September 30, 2025, was $20.1 million after the loan funding [25] Q&A Session Summary Question: Scale of U.S. O&P business - The company shipped approximately $900,000 worth of units, roughly 30 units, in the O&P channel during Q3 [31] Question: Customer acquisition cost improvements - The new head of marketing is reviewing the effectiveness of various advertising channels to generate more leads at a lower cost [32] Question: Backlog drop drivers - About 40% of the backlog drop was attributed to Germany, with some cleanup in the backlog during Q3 [34] Question: Future operating expenses - Operating expenses are expected to grow, but the company aims to manage them to generate operating leverage [36] Question: Pipeline adds and market saturation - Management believes there is still significant market opportunity and expects growth through innovative patient outreach [40] Question: Q4 growth expectations - Growth in Q4 is anticipated from fill units and authorizations/orders received within the quarter [42] Question: Debt decision rationale - The company believes it can manage the debt and expects to be closer to breakeven within 18 months [46] Question: O&P clinics training progress - Several hundred clinicians have undergone training, with goals to expand the number actively placing orders [54] Question: International business performance - Germany's success is attributed to a network of O&P partners and favorable reimbursement conditions [62]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $9.7 million, representing a 28% increase year-over-year, driven by a higher number of revenue units and an increase in average selling price (ASP) by 14% to approximately $54,200 [21][22] - Operating loss for Q2 2025 was $4.6 million, compared to an operating loss of $1.1 million in the prior year quarter [27] - Gross margin decreased to 62.7% from 70.8% in the prior year quarter, primarily due to higher material costs and overhead spending [25][26] Business Line Data and Key Metrics Changes - The company delivered 178 MyoPro revenue units in Q2 2025, up 13% year-over-year, with 91% of revenue recorded as shipment or delivery [21] - Medicare Part B patients represented 56% of revenue in Q2 2025, while Medicare Advantage revenue accounted for 20% of revenue, which was down slightly from the previous year [22][24] - The pipeline stood at 1,611 patients, a 37% increase year-over-year, with 816 patients added in Q2 2025, up 49% from the prior year quarter [23][24] Market Data and Key Metrics Changes - International revenue was $1.5 million in Q2 2025, representing 15% of total revenue and up 41% year-over-year, primarily from Germany [22] - The number of O and P orders doubled from Q1 to Q2 2025, indicating growth in that channel [15] Company Strategy and Development Direction - The company aims to achieve sustainable cash flow positive operations while expanding its MyoPro product line and improving conversion efficiency [6][19] - A shift in advertising strategy from social media to television is expected to improve lead quality and engagement [12][79] - The company is expanding its clinical referral program to increase education activities at rehab hospitals, which is anticipated to result in more high-quality patients entering the pipeline [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in converting leads to pipeline adds and the impact of Medicare Advantage plan behaviors on authorizations [16][18] - The company expects revenue growth in 2025 to be between 23% to 29%, reflecting the number of leads and pipeline adds year-to-date [20][34] - Management expressed confidence in the adjustments being made to improve results and emphasized the importance of Medicare Part B patients for growth [19][68] Other Important Information - The company undertook a headcount reduction impacting about 8% of its U.S. workforce to align operating expenses with revenue [12][13] - Cash burn for Q2 2025 was $10 million, with expectations of a normalized cash burn of approximately $4.9 million reflecting operational performance [30][31] Q&A Session Summary Question: Clarification on Q3 guidance and backlog conversions - Management noted an increase in fill units and a higher percentage of backlog, supporting the guidance of $9.5 to $10 million for Q3 [39][40] Question: Plans to accelerate O and P channel contributions - The company plans for significant growth in the O and P channel, with about 100 certified providers actively working to build a pipeline [44][46] Question: Advertising spend and cost per pipeline ad expectations - Advertising spending is expected to remain flat in Q3, with a potential decrease in Q4, while cost per pipeline ad is anticipated to decrease in Q3 compared to Q2 [49][50] Question: Challenges with Medicare Advantage authorizations - Management indicated that the authorization rate for Medicare Advantage patients is a significant headwind, with ongoing appeals processes affecting conversion rates [62][63] Question: Quality of leads from Facebook and future expectations - The company experienced lower quality leads from Facebook due to new privacy policies, leading to a shift in advertising strategy towards television [78][79] Question: Supply side costs and tariffs impact - Higher material costs were attributed to increased usage rather than pricing, with minimal impact from tariffs expected on gross margin [74][75] Question: Confidence in metrics and operational adjustments - Management expressed encouragement from July results and confidence in the plans put in place to address identified issues [68][69]

Financial Targets and Performance - Myomo aims to reach $100 million in annual revenue by 2028[18, 476] - The company targets a gross margin of 70-72% and an EBITDA margin of 15-20% in the long term[469] - Operating cash flow breakeven is projected at a revenue level of approximately $17 million to $18 million per quarter[469, 476] Revenue Channels - Direct billing accounted for 79% of Myomo's Q1 2025 revenue[16] - The O&P channel is targeted to contribute 20% of the total revenue by 2028[476] - International revenue constituted 13% of the company's Q1 2025 revenue[16] International Business (Germany) - In Germany, 10% of funding requests result in direct approval for MyoPro fitting, while 65% are routed through a 6-month trial[363, 364] - The conversion rate after a 6-month trial in Germany averages 35%[365, 369] - International revenue is projected to grow to $15 million by 2028[384] Cost Reduction and Efficiency - The company is targeting 200 bps of gross margin improvement on a quarterly basis by the end of 2026 through labor optimization and lean manufacturing implementation[339] - Myomo plans to insource core subassemblies, targeting a 15% cost reduction for FE & SP Joint by Q4 2025 and for Grasp and Elbow Motor Assembly by Q1 2026[341] Medicare Advantage (MAO) - Medicare Advantage Organizations (MAO) authorization rate in Q1 2025 is at a certain level, with industry-wide denial rates increasing[163] - Myomo has a 58% win rate for Administrative Law Judge (ALJ) hearings YTD[179]

Myomo (MYO) 2025 Investor Day Summary Company Overview - Myomo is focused on developing assistive technology for individuals with paralysis, particularly through their product, MyoPro, which is a myoelectric orthosis designed to help users regain movement in paralyzed arms [7][8][10]. Key Industry Insights - The company operates in the medical device industry, specifically within the orthotics and prosthetics sector, addressing a significant unmet need for patients with chronic arm paralysis [7][8]. - Myomo has established a direct provider business model, which allows them to bring their products directly to patients, enhancing accessibility and support [8][9]. Financial Performance and Goals - Myomo aims to achieve $100 million in revenue by 2028, building on a decade of consistent revenue growth [10]. - The company reported a gross margin of 70%, with potential for improvement as they scale operations [8]. Market Position and Strategy - Myomo has a first-mover advantage in the myoelectric orthosis market, particularly after receiving CMS reimbursement, which opens the market to Medicare-age patients in the U.S. [8][9]. - The revenue breakdown for Q1 indicates that 79% of revenue came from direct billing, 3% from the VA, and 13% from international sales, with plans to grow the O&P clinical channel [9][10]. Marketing and Lead Generation - The marketing strategy includes TV advertising, digital marketing, and clinical referrals, with a focus on reducing the cost per pipeline acquisition [31][32]. - The company utilizes a call center in Fort Worth, Texas, to handle inbound and outbound calls, aiming to efficiently convert leads into patients [56][60]. Patient Journey and Fulfillment Process - The patient journey begins with lead generation, followed by telehealth screenings to assess eligibility, and then moves to the fulfillment stage where custom devices are fabricated [19][25][94]. - The fulfillment process is complex, requiring precise measurements and customization for each patient, which is critical for the effectiveness of the MyoPro device [97][98]. Challenges and Considerations - The company faces challenges related to patient eligibility, as not all patients qualify for the MyoPro due to varying clinical conditions [69][70]. - There is a need for continuous education and awareness among patients, therapists, and physicians to ensure proper understanding and utilization of the MyoPro [22][23]. Leadership and Team Structure - The leadership team includes experienced professionals from various backgrounds, emphasizing a commitment to patient care and innovative solutions [11][12]. - The company is structured to allow for efficient scaling of operations, particularly in the intake and telehealth screening processes [63][66]. Conclusion - Myomo is well-positioned to capitalize on the growing demand for assistive technologies for individuals with paralysis, with a clear strategy for growth and a strong focus on patient outcomes and satisfaction [7][10].

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $9,800,000, representing a 162% increase year over year, driven by a higher number of revenue units and an increased average selling price (ASP) [20][21] - The company delivered 182 MyoPro revenue units in Q1, up 100% from the previous year, with ASP increasing by approximately 31% to around $54,000 [11][21] - Gross margin for Q1 2025 was 67.2%, compared to 61.2% in the prior year, primarily due to a higher ASP and better fixed cost absorption [26] - Operating loss for Q1 2025 was $3,500,000, a 9% improvement from a loss of $3,900,000 in Q1 2024 [27][28] Business Line Data and Key Metrics Changes - The O and P revenue was $475,000 in Q1, up 87% year over year, but down sequentially due to seasonality [14] - The international business, primarily in Germany, generated over $1,300,000 in revenue, representing a 42% year-over-year increase [11][22] Market Data and Key Metrics Changes - Medicare Part B patients accounted for 60% of total revenue in Q1, up from 57% in the previous quarter, indicating strong growth in this segment [11][21] - Medicare Advantage revenue represented 17% of Q1 revenue, reflecting an 18% year-over-year increase, although growth is lagging due to high denial rates [21][22] Company Strategy and Development Direction - The company is focused on continuous innovation, having launched the MyoPro 2X and the Mark II clinical unit, aimed at enhancing patient independence and expanding the O and P distribution channel [6][7] - Plans for further expansion include increasing manufacturing capacity and enhancing marketing efforts to drive lead generation and patient engagement [12][32] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in lead generation due to changes in social media advertising policies but reported a rebound in lead generation in March and April [10][32] - The company expects Q2 revenue to be slightly lower than Q1 but reaffirms its financial targets for the year, projecting full-year revenue between $50,000,000 and $53,000,000, representing growth of 54% to 66% over 2024 [30][31] Other Important Information - The company has signed contracts covering approximately 25,000,000 lives, including several new state Blue Cross Blue Shield plans, and is negotiating with national health insurance plans [18][64] - The company is actively working to improve insurance access and reduce denial rates through advocacy and legal engagement [17][65] Q&A Session Summary Question: Can you elaborate on the workaround around the Meta issue affecting advertising efficiency? - Management indicated that changes in Meta's algorithms impacted ad targeting, but adjustments made with their agency have led to a record number of leads in April, suggesting sustainability in improvements [37][38] Question: What is the expected cost per pipeline add moving forward? - The cost per lead in April was approximately half of that in January and February, with expectations to maintain efficiency around $1,400 to $1,500 for the year [39][40] Question: How does the authorization rate for the pipeline look? - The authorization rate was affected by backend loading of pipeline adds and high denial rates from Medicare Advantage plans, which are currently around 30% [51][52] Question: What is the outlook for gross margins going forward? - Management expects slightly lower gross margins in Q2 due to lower volume but anticipates approaching 70% gross margins in the second half of the year [53] Question: What is the confidence level in achieving the full-year guidance? - Management reiterated confidence in achieving full-year guidance, citing historical revenue patterns and increased advertising efforts to fill the pipeline [56]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $9,800,000, representing a 162% increase year over year, driven by a higher number of revenue units and an increased average selling price (ASP) [18][19] - The company delivered 182 MyoPro revenue units in Q1, up 100% from Q1 2024, with ASP increasing by approximately 31% to around $54,000 [19][9] - Gross margin for Q1 2025 was 67.2%, compared to 61.2% in the prior year quarter, primarily due to a higher ASP and better fixed cost absorption [24] - Operating loss for Q1 2025 was $3,500,000, a decrease of 9% compared to the $3,900,000 loss in Q1 2024 [25][26] Business Line Data and Key Metrics Changes - The O and P revenue was $475,000 in Q1, up 87% year over year, but down sequentially due to seasonality [12] - The company added a record 700 medically qualified candidates to its patient pipeline during Q1, ending the quarter with nearly 1,500 patients in the process of obtaining MyoPro [9][20] - International revenue, primarily from Germany, was $1,300,000 in Q1, representing 13% of total revenue and up 42% year over year [19][10] Market Data and Key Metrics Changes - Medicare Part B patients represented 60% of total revenue in Q1, up from 57% in the previous quarter, highlighting the company's success in educating this patient population [19] - Medicare Advantage revenue was 17% of Q1 revenue, reflecting an 18% year-over-year increase, although growth is lagging due to high denial rates [19][14] Company Strategy and Development Direction - The company is focused on continuous innovation, having launched two product upgrades in 2025, including the MyoPro 2X, aimed at improving independent device use [6][9] - The company is expanding its O and P distribution channel by training clinicians and establishing certified MyoPro centers of excellence [12][11] - The company plans to continue investing in marketing, product development, and distribution channels to achieve cash flow positivity by the end of 2025 [16][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in lead generation due to changes in social media algorithms but reported a record number of leads in April, indicating a rebound [8][29] - The company expects Q2 revenue to be slightly lower than Q1 but reaffirms its financial targets for the year, projecting full-year revenue between $50,000,000 and $53,000,000 [28][9] - Management expressed confidence in achieving its guidance for the year, citing a historical trend of higher revenue in the second half of the year [55][28] Other Important Information - The company completed a successful capital raise at the end of 2024 to fund growth plans for 2025 and beyond [16] - The company is actively working to improve insurance access and has signed contracts covering 25,000,000 lives, including several new state Blue Cross Blue Shield plans [16][64] Q&A Session Summary Question: Can you elaborate on the workaround around the Meta issue driving advertising efficiency improvement? - Management explained that changes in Meta's algorithms affected ad targeting, but adjustments made with their agency led to a record number of leads in April, indicating sustainability in improvements [35][36] Question: What is the expected cost per pipeline add moving forward? - Management indicated that while the cost per pipeline add in April was significantly lower than in January and February, they expect it to stabilize around $1,400 to $1,500 for 2024 [37] Question: What are the drivers behind the percentage of pipeline drops? - Management noted that pipeline drops are often due to inability to contact patients again or changes in insurance, with clinical presentation changes also affecting backlog [38][40] Question: How should investors think about revenue cadence in Q3 and Q4? - Management stated that with a higher percentage of Medicare revenue, they do not need as high a backlog for revenue forecasts, and they expect to maintain fill percentages [41][42] Question: Can you provide insights on the O and P channel growth? - Management highlighted the O and P channel as a significant growth opportunity, with good reimbursement and margins, despite challenges in staffing and training [72][73] Question: What is the outlook for international markets, particularly Germany? - Management confirmed plans to expand the team in Germany and increase investments in social media advertising and clinic recruitment due to strong growth in that market [77][78]